AIM: To study the @entity137 profile and response rates of weekly @entity1311 given as neoadjuvant chemotherapy (NACT) in @entity1 with locally advanced @entity0 . MATERIALS AND METHODS: The study was planned as a single arm, prospective phase II study. Twenty-six @entity1 with locally advanced @entity0 were enrolled in the study from December 2006 to October 2007. These @entity1 underwent NACT with weekly @entity1311 at 100 mg/m(2) for 8 consecutive weeks followed by surgery. This was followed by @entity4349 -based chemotherapy for three to four cycles followed by radiation. The @entity1 received standard adjuvant hormonal therapy. The @entity1 were carefully monitored for side-effects using common @entity137 criteria. The clinical and pathological response rates were documented. The response rates were descriptively stated. RESULTS: The median age of the @entity1 was 52 years (30-67 years) and the median @entity5 size was 7 cm (2.5-15 cm). Of the 208 planned weekly cycles, 207 could be given. The rates of grade 3-4 @entity1398 , @entity882 and @entity16 were 4, 12 and 4%, respectively. A complete clinical response was observed in 10 @entity1 (38.5%) and a completed pathological response, defined as the absence of invasive @entity5 from the breast and axillary nodes, was seen in 11.5% of @entity1 . Breast-conserving surgery was possible in 23% of @entity1 . CONCLUSION: The regimen of weekly single agent @entity1311 is feasible in @entity1 with locally advanced @entity0 with acceptable @entity137 . It resulted in a pathological response rate that was comparable with other regimens in this group of advanced stage @entity1 . Considering the efficacy and low @entity137 of this regimen, it is worth exploring in larger studies.

Single agent weekly XXXX as neoadjuvant chemotherapy in locally advanced @entity0 : a feasibility study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumour'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
